Catalent Pharma Solutions is betting big on the Chinese market, launching two joint ventures for its Softgel Technologies and Clinical Supply Solutions businesses.
As many as 2,868 people have died in Indian clinical trials over the past 7 years, and sponsors and CROs have paid out compensation in just 45 of those instances, according to India's Business Standard.
Maryland's Accelovance is stepping up its clinical research capabilities, buying Radiant Development, the CRO arm of Radiant Research.
After clearing about $500 million in revenue last year, Chinese CRO giant WuXi PharmaTec is expecting between 13% and 15% growth in 2013, counting on an increase in big-name partnerships and an expansion of the local drug market.
Canadian CDMO Patheon more than doubled its losses last quarter, but the company says that's just a hiccup as it integrates the newly acquired Banner Pharmacaps and pushes toward its goal of $1 billion in annual revenue.
PRA has snatched up CRO ClinStar, giving it a foothold in the growing Eastern European outsourcing market.
According to CenterWatch's latest Global Investigative Site Relationship survey, clinical trial sites voted Biogen Idec, Forest Laboratories and Bayer the best sponsors, giving them the best marks on 36 relationship attributes.
Covance is stepping up its personalized medicine services, teaming up with the biomarker-focused M2Gen to better identify ideal patients for oncology drug trials.
As the science behind innovative treatments gets more and more sophisticated, poor solubility has become a serious concern for drug developers. With that in mind, Chinese CRO Crystal Pharmatech has partnered with drug delivery-focused contractor Particle Sciences to offer formulation solutions to clients.
Fresh off spending $72 million on IT outfit Liquent, Parexel says it's hardly finished expanding through M&A, keeping its eye on small technology companies and contractors in the Middle East for future deals.
Capsugel is doubling down on its formulation and manufacturing business, buying Scotland's Encap Drug Delivery to expand its services.
Synteract has closed a deal to acquire Germany's Harrison Clinical Research, rebranding itself as SynteractHCR and expanding its reach to 16 countries.
French CRO CiToxLAB posted 25% revenue growth in 2012, excellent results that shine compared to the overall results for the preclinical research market.
ShangPharma is putting its plans to go private in front of shareholders on March 20, asking for approval on a deal that would sell the company to a group of private equity outfits for $173 million.
Last week's big news that Quintiles is finally going public left one burning question: How much will the company raise in its IPO?
CMO Lonza has signed a three-year, $6.9 million agreement with NIH's Center for Regenerative Medicine, signing on to supply stem cells for research purposes.
Now that it has paid about $6.1 million for Warnex's bioanalytics business, France's Biotrial Research is launching an offering all its own.
In 2012, 436 people died during clinical trials in India, a number nearly unchanged from the previous year despite an increase in governmental scrutiny.
Pfizer is still trimming down its R&D budget, confirming to FierceBiotech over the weekend that it will shutter its San Diego-based CovX and cut 100 jobs.
Irish CRO Icon pulled down a monster fourth quarter, with revenue skyrocketing 24% to $300 million, and the company predicts an even brighter 2013, projecting annual revenue of up to $1.3 billion, good for a 12% jump.